Anticancer activity of bisphosphonates in breast cancer

Anti-Cancer Agents in Medicinal Chemistry

Volumn 12, Issue 2, 2012, Pages 114-122

  Gnant, Michael ^a  

^a MEDICAL UNIVERSITY OF VIENNA   (Austria)

Author keywords

Adjuvant therapy; Anticancer; Bisphosphonate; Breast cancer; Zoledronic acid

Indexed keywords

ANASTROZOLE; BISPHOSPHONIC ACID DERIVATIVE; CLODRONIC ACID; GOSERELIN; GROWTH FACTOR; TAMOXIFEN; ZOLEDRONIC ACID;

ANTINEOPLASTIC ACTIVITY; ARTICLE; BONE DEVELOPMENT; BONE MARROW; BONE METASTASIS; BREAST CANCER; CANCER GROWTH; CANCER RECURRENCE; CANCER RISK; CANCER THERAPY; CARCINOGENESIS; CELL DIFFERENTIATION; CLINICAL TRIAL; DISEASE COURSE; DRUG SAFETY; DRUG TOLERABILITY; HORMONAL THERAPY; HUMAN; JAW OSTEONECROSIS; KIDNEY FUNCTION; MICROENVIRONMENT; OSSIFICATION; OSTEOCLAST; OSTEOLYSIS; POSTMENOPAUSE; PRACTICE GUIDELINE; PRECANCER; PREMENOPAUSE; SIDE EFFECT;

EID: 84856262381     PISSN: 18715206     EISSN: 18755992     Source Type: Journal    
DOI: 10.2174/187152012799014931     Document Type: Article

References (59)

1. Garcia, M.; Jemal, A.; Ward, E. M.; Center, M. M.; Hao, Y.; Siegel, R. L.; Thun, M. J. In Global Cancer Facts & Figures 2007, American Cancer Society, Atlanta, GA, 2007, Atlanta, GA, 2007.
2. Mansell, J.; Monypenny, I. J.; Skene, A. I.; Abram, P.; Carpenter, R.; Gattuso, J. M.; Wilson, C. R.; Angerson, W. J.; Doughty, J. C., Patterns and predictors of early recurrence in postmenopausal women with estrogen receptor-positive early breast cancer. Breast Cancer Res. Treat., 2009, 117(1), 91-98.
3. Baum, M.; Budzar, A. U.; Cuzick, J.; Forbes, J.; Houghton, J. H.; Klijn, J. G.; Sahmoud, T., Anastrozole alone or in combination with tamoxifen versus tamoxifen alone for adjuvant treatment of postmenopausal women with early breast cancer: first results of the ATAC randomised trial. Lancet, 2002, 359(9324), 2131-2139.
4. Thurlimann, B.; Keshaviah, A.; Coates, A. S.; Mouridsen, H.; Mauriac, L.; Forbes, J. F.; Paridaens, R.; Castiglione-Gertsch, M.; Gelber, R. D.; Rabaglio, M.; Smith, I.; Wardley, A.; Price, K. N.; Goldhirsch, A., A comparison of letrozole and tamoxifen in postmenopausal women with early breast cancer. N. Engl. J. Med., 2005, 353(26), 2747-2757.
5. Jemal, A.; Siegel, R.; Ward, E.; Murray, T.; Xu, J.; Smigal, C.; Thun, M. J., Cancer statistics, 2006. CA Cancer J. Clin., 2006, 56(2), 106-130.
6. Braun, S.; Vogl, F. D.; Naume, B.; Janni, W.; Osborne, M. P.; Coombes, R. C.; Schlimok, G.; Diel, I. J.; Gerber, B.; Gebauer, G.; Pierga, J. Y.; Marth, C.; Oruzio, D.; Wiedswang, G.; Solomayer, E. F.; Kundt, G.; Strobl, B.; Fehm, T.; Wong, G. Y.; Bliss, J.; Vincent-Salomon, A.; Pantel, K., A pooled analysis of bone marrow micrometastasis in breast cancer. N. Engl. J. Med., 2005, 353(8), 793-802.
7. Kim, M. Y.; Oskarsson, T.; Acharyya, S.; Nguyen, D. X.; Zhang, X. H.; Norton, L.; Massague, J., Tumor self-seeding by circulating cancer cells. Cell, 2009, 139(7), 1315-1326.
8. Diel, I. J.; Jaschke, A.; Solomayer, E. F.; Gollan, C.; Bastert, G.; Sohn, C.; Schuetz, F., Adjuvant oral clodronate improves the overall survival of primary breast cancer patients with micrometastases to the bone marrow: a long-term follow-up. Ann. Oncol., 2008, 19(12), 2007-2011.
9. Clezardin, P., Anti-tumour activity of zoledronic acid. Cancer Treat. Rev., 2005, 31(suppl 3), 1-8.
10. Winter, M. C.; Holen, I.; Coleman, R. E., Exploring the antitumour activity of bisphosphonates in early breast cancer. Cancer Treat. Rev., 2008, 34(5), 453-475.
11. Gnant, M., Bisphosphonates in the prevention of disease recurrence: current results and ongoing trials. Curr. Cancer Drug Targets, 2009, 9(7), 824-833.
12. Coleman, R. E., Bisphosphonates: clinical experience. Oncologist, 2004, 9(suppl 4), 14-27.
13. Coleman, R. E., Metastatic bone disease: clinical features, pathophysiology and treatment strategies. Cancer Treat. Rev., 2001, 27(3), 165-176.
14. Saad, F.; Lipton, A.; Cook, R.; Chen, Y. M.; Smith, M.; Coleman, R., Pathologic fractures correlate with reduced survival in patients with malignant bone disease. Cancer, 2007, 110(8), 1860-1867.
15. Padalecki, S. S.; Guise, T. A., Actions of bisphosphonates in animal models of breast cancer. Breast Cancer Res., 2002, 4(1), 35-41.
16. Lipton, A.; Chapman, J. W.; Demers, L.; Shepherd, L.; Han, L.; Wilson, C. F.; Pritchard, K. I.; Leitzel, K.; Ali, S. M.; Pollak, M., Elevated bone resorption predicts shorter recurrence-free survival for bone metastasis in breast cancer [abstract]. Presented at: Primary Therapy of Early Breast Cancer 11th International Conference; March 11-14, 2009; St. Gallen, Switzerland. Abstract 244.
17. Meads, M. B.; Hazlehurst, L. A.; Dalton, W. S., The bone marrow microenvironment as a tumor sanctuary and contributor to drug resistance. Clin. Cancer Res., 2008, 14(9), 2519-2526.
18. Bidard, F. C.; Kirova, Y. M.; Vincent-Salomon, A.; Alran, S.; de Rycke, Y.; Sigal-Zafrani, B.; Sastre-Garau, X.; Mignot, L.; Fourquet, A.; Pierga, J. Y., Disseminated tumor cells and the risk of locoregional recurrence in nonmetastatic breast cancer. Ann. Oncol., 2009, 20(11), 1836-1841.
19. Cristofanilli, M.; Hayes, D. F.; Budd, G. T.; Ellis, M. J.; Stopeck, A.; Reuben, J. M.; Doyle, G. V.; Matera, J.; Allard, W. J.; Miller, M. C.; Fritsche, H. A.; Hortobagyi, G. N.; Terstappen, L. W., Circulating tumor cells: a novel prognostic factor for newly diagnosed metastatic breast cancer. J. Clin. Oncol., 2005, 23(7), 1420-1430.
20. Mundy, G. R., Metastasis to bone: causes, consequences and therapeutic opportunities. Nat. Rev. Cancer, 2002, 2(8), 584-593.
21. Winter, M. C.; Coleman, R. E., Bisphosphonates in breast cancer: teaching an old dog new tricks. Curr. Opin. Oncol., 2009, 21(6), 499-506.
22. Abe, Y.; Muto, M.; Nieda, M.; Nakagawa, Y.; Nicol, A.; Kaneko, T.; Goto, S.; Yokokawa, K.; Suzuki, K., Clinical and immunological evaluation of zoledronate-activated Vgamma9 gammadelta T-cell-based immunotherapy for patients with multiple myeloma. Exp. Hematol., 2009, 37(8), 956-968.
23. Benzaid, I.; Clezardin, P., Nitrogen-containing bisphosphonates and human γ δT cells. IBMS BoneKEy, 2010, 7(6), 208-217.
24. Powles, T.; Paterson, A.; McCloskey, E.; Schein, P.; Scheffler, B.; Tidy, A.; Ashley, S.; Smith, I.; Ottestad, L.; Kanis, J., Reduction in bone relapse and improved survival with oral clodronate for adjuvant treatment of operable breast cancer [ISRCTN83688026]. Breast Cancer Res., 2006, 8(2), R13.
25. Saarto, T.; Vehmanen, L.; Virkkunen, P.; Blomqvist, C., Ten-year follow-up of a randomized controlled trial of adjuvant clodronate treatment in node-positive breast cancer patients. Acta Oncol., 2004, 43(7), 650-656.
26. Kristensen, B.; Ejlertsen, B.; Mouridsen, H. T.; Jensen, M. B.; Andersen, J.; Bjerregaard, B.; Cold, S.; Edlund, P.; Ewertz, M.; Kamby, C.; Lindman, H.; Nordenskjold, B.; Bergh, J., Bisphosphonate treatment in primary breast cancer: results from a randomised comparison of oral pamidronate versus no pamidronate in patients with primary breast cancer. Acta Oncol., 2008, 47(4), 740-746.
27. Gnant, M.; Mlineritsch, B.; Schippinger, W.; Luschin-Ebengreuth, G.; Postlberger, S.; Menzel, C.; Jakesz, R.; Seifert, M.; Hubalek, M.; Bjelic-Radisic, V.; Samonigg, H.; Tausch, C.; Eidtmann, H.; Steger, G.; Kwasny, W.; Dubsky, P.; Fridrik, M.; Fitzal, F.; Stierer, M.; Rucklinger, E.; Greil, R.; Marth, C., Endocrine therapy plus zoledronic acid in premenopausal breast cancer. N. Engl. J. Med., 2009, 360(7), 679-691.
28. Gnant, M.; Mlineritsch, B.; Stoeger, H.; Luschin-Ebengreuth, G.; Heck, D.; Menzel, C.; Jakesz, R.; Seifert, M.; Hubalek, M.; Pristauz, G.; Bauernhofer, T.; Eidtmann, H.; Eiermann, W.; Steger, G.; Kwasny, W.; Dubsky, P.; Hochreiner, G.; Forsthuber, E. P.; Fesl, C.; Greil, R., Adjuvant endocrine therapy plus zoledronic acid in premenopausal women with early-stage breast cancer: 62-month follow-up from the ABCSG-12 randomised trial. Lancet Oncol., 2011, 12(7), 631-641.
29. Eidtmann, H.; de Boer, R.; Bundred, N.; Llombart-Cussac, A.; Davidson, N.; Neven, P.; von Minckwitz, G.; Miller, J.; Schenk, N.; Coleman, R., Efficacy of zoledronic acid in postmenopausal women with early breast cancer receiving adjuvant letrozole: 36-month results of the ZO-FAST study. Ann. Oncol., 2010, 21, 2188-2194.
30. Coleman, R.; Bundred, N.; de Boer, R.; Llombart, A.; Campbell, I.; Neven, P.; Barrios, C.; Miller, J.; Dias, R.; Brufsky, A., Impact of zoledronic acid in postmenopausal women with early breast cancer receiving adjuvant letrozole: Z-FAST, ZO-FAST, and EZO-FAST [abstract]. Presented at: 32nd Annual San Antonio Breast Cancer Symposium; December 9-13, 2009; San Antonio, TX; Abstract 4082.
31. de Boer, R.; Bundred, N.; Eidtmann, H.; Llombart, A.; Neven, P.; von Minckwitz, G.; Martin, N.; Modi, A.; Coleman, R., The effect of zoledronic acid on aromatase inhibitor associated bone loss in postmenopausal women with early breast cancer receiving adjuvant letrozole: the ZO-FAST study 5-year final follow-up [abstract]. Presented at: 33rd Annual San Antonio Breast Cancer Symposium; December 8-12, 2010; San Antonio, TX. Abstract P5-11-01.
32. Coleman, R. E.; Marshall, H.; Cameron, D.; Dodwell, D.; Burkinshaw, R.; Keane, M.; Gil, M.; Houston S. J.; Grieve, R. J.; Barrett-Lee, P. J.; Ritchie, D.; Pugh, J.; Gaunt, C.; Rea, U.; Peterson, J.; Davies, C.; Hiley, V.; Gregory, W.; Bell, R., for the AZURE Investigators, Breast-Cancer Adjuvant Therapy with Zoledronic Acid. N. Engl. J. Med., 2001, 365(15), 1396-1405.
33. Coleman, R. E.; Winter, M. C.; Cameron, D.; Bell, R.; Dodwell, D.; Keane, M. M.; Gil, M.; Ritchie, D.; Passos-Coelho, J. L.; Wheatley, D.; Burkinshaw, R.; Marshall, S. J.; Thorpe, H., The effects of adding zoledronic acid to neoadjuvant chemotherapy on tumour response: exploratory evidence for direct antitumour activity in breast cancer. Br. J. Cancer, 2010, 102(7), 1099-1105.
34. Aft, R.; Naughton, M.; Trinkaus, K.; Watson, M.; Ylagan, L.; Chavez-MacGregor, M.; Zhai, J.; Kuo, S.; Shannon, W.; Diemer, K.; Herrmann, V.; Dietz, J.; Ali, A.; Ellis, M.; Weiss, P.; Eberlein, T.; Ma, C.; Fracasso, P. M.; Zoberi, I.; Taylor, M.; Gillanders, W.; Pluard, T.; Mortimer, J.; Weilbaecher, K., Effect of zoledronic acid on disseminated tumour cells in women with locally advanced breast cancer: an open label, randomised, phase 2 trial. Lancet Oncol., 2010, 11(5), 421-428.
35. Lin, A. Y.; Park, J. W.; Scott, J.; Melisko, M.; Goga, A.; Moasser, M.; Moore, D. H.; Rugo, H. S., Zoledronic acid as adjuvant therapy for women with early stage breast cancer and disseminated tumor cells in bone marrow [abstract]. J. Clin. Oncol., 2008, 26, 20s. Abstract 559.
36. Rack, B.; Juckstock, J.; Genss, E. M.; Schoberth, A.; Schindlbeck, C.; Strobl, B.; Heinrigs, M.; Rammel, G.; Zwingers, T.; Sommer, H.; Friese, K.; Janni, W., Effect of zoledronate on persisting isolated tumour cells in patients with early breast cancer. Anticancer Res., 2010, 30(5), 1807-1813.
37. Solomayer, E. F.; Gebauer, G.; Hirnle, P.; Janni, W.; Lück, H.-J.; Becker, S.; Huober, J.; Kraemer, B.; Wackwitz, B.; Fehm, T., Influence of zoledronic acid on disseminated tumor cells (DTC) in primary breast cancer patients [abstract]. Cancer Res., 2009, 69(suppl 2), 170s-171s. Abstract 2048.
38. Vantourout, P.; Mookerjee-Basu, J.; Rolland, C.; Pont, F.; Martin, H.; Davrinche, C.; Martinez, L. O.; Perret, B.; Collet, X.; Perigaud, C.; Peyrottes, S.; Champagne, E., Specific requirements for Vgamma9Vdelta2 T cell stimulation by a natural adenylated phosphoantigen. J. Immunol., 2009, 183(6), 3848-3857.
39. Hoff, A. O.; Toth, B. B.; Altundag, K.; Johnson, M. M.; Warneke, C. L.; Hu, M.; Nooka, A.; Sayegh, G.; Guarneri, V.; Desrouleaux, K.; Cui, J.; Adamus, A.; Gagel, R. F.; Hortobagyi, G. N., Frequency and risk factors associated with osteonecrosis of the jaw in cancer patients treated with intravenous bisphosphonates. J. Bone Miner. Res., 2008, 23(6), 826-836.
40. Ripamonti, C. I.; Maniezzo, M.; Campa, T.; Fagnoni, E.; Brunelli, C.; Saibene, G.; Bareggi, C.; Ascani, L.; Cislaghi, E., Decreased occurrence of osteonecrosis of the jaw after implementation of dental preventive measures in solid tumour patients with bone metastases treated with bisphosphonates. The experience of the National Cancer Institute of Milan. Ann. Oncol., 2009, 20(1), 137-145.
41. Dimopoulos, M. A.; Kastritis, E.; Bamia, C.; Melakopoulos, I.; Gika, D.; Roussou, M.; Migkou, M.; Eleftherakis-Papaiakovou, E.; Christoulas, D.; Terpos, E.; Bamias, A., Reduction of osteonecrosis of the jaw (ONJ) after implementation of preventive measures in patients with multiple myeloma treated with zoledronic acid. Ann. Oncol., 2009, 20(1), 117-120.
42. Mauri, D.; Valachis, A.; Polyzos, I. P.; Polyzos, N. P.; Kamposioras, K.; Pesce, L. L., Osteonecrosis of the jaw and use of bisphosphonates in adjuvant breast cancer treatment: a metaanalysis. Breast Cancer Res. Treat., 2009, 116(3), 433-439.
43. Prolia [summary of medicinal product characteristics]. Breda, The Netherlands: Amgen Europe B.V.; 2010.
44. Xgeva (denosumab) injection [package insert]. Thousand Oaks, CA: Amgen Inc.; 2010.
45. Fizazi, K.; Carducci, M.; Smith, M.; Damiao, R.; Brown, J.; Karsh, L.; Milecki, P.; Shore, N.; Rader, M.; Wang, H.; Jiang, Q.; Tadros, S.; Dansey, R.; Goessl, C., Denosumab versus zoledronic acid for treatment of bone metastases in men with castration-resistant prostate cancer: a randomised, double-blind study. Lancet, 2011, 377(9768), 813-822.
46. Henry, D. H.; Costa, L.; Goldwasser, F.; Hirsh, V.; Hungria, V.; Prausova, J.; Scagliotti, G. V.; Sleeboom, H.; Spencer, A.; Vadhan-Raj, S.; von Moos, R.; Willenbacher, W.; Woll, P. J.; Wang, J.; Jiang, Q.; Jun, S.; Dansey, R.; Yeh, H., Randomized, double-blind study of denosumab versus zoledronic acid in the treatment of bone metastases in patients with advanced cancer (excluding breast and prostate cancer) or multiple myeloma. J. Clin. Oncol., 2011, 29(9), 1125-1132.
47. Stopeck, A. T.; Lipton, A.; Body, J. J.; Steger, G. G.; Tonkin, K.; de Boer, R. H.; Lichinitser, M.; Fujiwara, Y.; Yardley, D. A.; Viniegra, M.; Fan, M.; Jiang, Q.; Dansey, R.; Jun, S.; Braun, A., Denosumab compared with zoledronic acid for the treatment of bone metastases in patients with advanced breast cancer: a randomized, double-blind study. J. Clin. Oncol., 2010, 28, 5132-5139.
48. Vehmanen, L.; Elomaa, I.; Blomqvist, C.; Saarto, T., Tamoxifen treatment after adjuvant chemotherapy has opposite effects on bone mineral density in premenopausal patients depending on menstrual status. J. Clin. Oncol., 2006, 24(4), 675-680.
49. Gnant, M.; Mlineritsch, B.; Luschin-Ebengreuth, G.; Kainberger, F.; Kassmann, H.; Piswanger-Solkner, J. C.; Seifert, M.; Ploner, F.; Menzel, C.; Dubsky, P.; Fitzal, F.; Bjelic-Radisic, V.; Steger, G.; Greil, R.; Marth, C.; Kubista, E.; Samonigg, H.; Wohlmuth, P.; Mittlbock, M.; Jakesz, R., Adjuvant endocrine therapy plus zoledronic acid in premenopausal women with early-stage breast cancer: 5-year follow-up of the ABCSG-12 bone-mineral density substudy. Lancet Oncol., 2008, 9(9), 840-849.
50. Sverrisdottir, A.; Fornander, T.; Jacobsson, H.; von Schoultz, E.; Rutqvist, L. E., Bone mineral density among premenopausal women with early breast cancer in a randomized trial of adjuvant endocrine therapy. J. Clin. Oncol., 2004, 22(18), 3694-3699.
51. Aebi, S.; Davidson, T.; Gruber, G.; Castiglione, M., Primary breast cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann. Oncol., 2010, 21(suppl 5), v9-v14.
52. Forbes, J. F.; Cuzick, J.; Buzdar, A.; Howell, A.; Tobias, J. S.; Baum, M., Effect of anastrozole and tamoxifen as adjuvant treatment for early-stage breast cancer: 100-month analysis of the ATAC trial. Lancet Oncol., 2008, 9(1), 45-53.
53. Rabaglio, M.; Sun, Z.; Price, K. N.; Castiglione-Gertsch, M.; Hawle, H.; Thurlimann, B.; Mouridsen, H.; Campone, M.; Forbes, J. F.; Paridaens, R. J.; Colleoni, M.; Pienkowski, T.; Nogaret, J. M.; Lang, I.; Smith, I.; Gelber, R. D.; Goldhirsch, A.; Coates, A. S., Bone fractures among postmenopausal patients with endocrineresponsive early breast cancer treated with 5 years of letrozole or tamoxifen in the BIG 1-98 trial. Ann. Oncol., 2009, 20(9), 1489-1498.
54. Lipton, A., Should bisphosphonates be utilized in the adjuvant setting for breast cancer? Breast Cancer Res. Treat., 2010, 122(3), 627-636.
55. Chlebowski, R. T.; Chen, Z.; Cauley, J. A.; Anderson, G.; Rodabough, R. J.; McTiernan, A.; Lane, D. S.; Manson, J. E.; Snetselaar, L.; Yasmeen, S.; O'Sullivan, M. J.; Safford, M.; Hendrix, S. L.; Wallace, R. B., Oral bisphosphonate use and breast cancer incidence in postmenopausal women. J. Clin. Oncol., 2010, 28, 3582-3590.
56. Newcomb, P. A.; Trentham-Dietz, A.; Hampton, J. M., Bisphosphonates for osteoporosis treatment are associated with reduced breast cancer risk. Br. J. Cancer, 2010, 102(5), 799-802.
57. Rennert, G.; Pinchev, M.; Rennert, H. S., Use of bisphosphonates and risk of postmenopausal breast cancer. J. Clin. Oncol., 2010, 28, 3577-3581.
58. Santini, D.; Vincenzi, B.; Galluzzo, S.; Battistoni, F.; Rocci, L.; Venditti, O.; Schiavon, G.; Angeletti, S.; Uzzalli, F.; Caraglia, M.; Dicuonzo, G.; Tonini, G., Repeated intermittent low-dose therapy with zoledronic acid induces an early, sustained, and long-lasting decrease of peripheral vascular endothelial growth factor levels in cancer patients. Clin. Cancer Res., 2007, 13(15 pt 1), 4482-4486.
59. Stresing, V.; Daubine, F.; Benzaid, I.; Monkkonen, H.; Clezardin, P., Bisphosphonates in cancer therapy. Cancer Lett., 2007, 257(1), 16-35.